Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia
NCT05832216Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in platelet transfusion refractoriness (PTR), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Percentage of patients with platelet transfusion responsiveness at 12 weeks. Started Apr 2023; status: completed.
02
Drugs
daratumumab
03
Conditions
platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on NCT05832216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832216.